Updated:
Latterell Venture Partners
Latterell Venture Partners is an early-stage life sciences VC firm founded by Pat Latterell, known for translating medical devices from bench to bedside.
Latterell Venture Partners
Latterell Venture Partners operates as an early-stage venture capital firm headquartered in San Ramon, California. Founded by Pat Latterell, the firm targets company creation and seed through Series A investments in life sciences, with a focus on medical devices, biotechnology, and healthcare services. Latterell's model emphasizes concentrated portfolios and high engagement with founding teams rather than passive check-writing at scale. The firm deploys capital primarily into medical device innovation, diagnostics, and biotech platforms. Latterell Venture Partners participates in direct equity deals and often leads or co-leads early rounds where the science is still translating from bench to bedside. Confirmed portfolio companies include Ardian (renal denervation, acquired by Medtronic) and Acclarent (ENT devices, acquired by Johnson & Johnson). Geography is heavily weighted toward the West Coast innovation corridor, with additional investments across the broader United States. The firm maintains a lean partnership structure. While total AUM is not publicly disclosed, Latterell has raised multiple funds over its history. Its size lets the firm access deals where larger venture funds are structurally excluded from early-stage check sizes. The partnership draws on operating and clinical advisors rather than maintaining a large in-house investment staff. Latterell Venture Partners stands apart from generalist healthcare funds by staying almost exclusively in the medical-device and tools lane — a track that traces directly to Latterell's own biomedical-engineering background and his tenure at Morgenthaler Ventures. The firm benefits from a sourcing model that relies on relationships with academic medical centers and practicing surgeons who surface unmet clinical needs before the syndicate-view VC crowd arrives.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Ramon
Corporate office
San Ramon, CA, United States
Principals
Pat Latterell
Founder and Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Latterell Venture Partners?
Pat Latterell, the founder and managing director, leads investment decisions. His background in biomedical engineering and his tenure at Morgenthaler Ventures shaped the firm's focus on medical devices and tools. Day-to-day evaluation leverages a network of clinical advisors rather than a large partnership committee.
What investment stages does Latterell Venture Partners typically target?
The firm concentrates almost entirely on early-stage opportunities — seed and Series A rounds where the science is solidifying around a specific clinical application. It avoids growth equity and late-stage biotech financings where large syndicates and crossover funds dominate. The model is designed for high ownership at company formation.
Which sectors does Latterell Venture Partners explicitly avoid?
The firm does not invest in enterprise software, consumer internet, fintech, or generalist technology. Within healthcare, it has historically avoided small-molecule therapeutics and large Phase III biotech financings that require substantial capital reserves. Investments stay close to interventional medicine and tools.
Does Latterell Venture Partners participate in fund commitments or only direct deals?
Latterell Venture Partners invests directly in portfolio companies and takes board seats where appropriate. It is not known to operate as a fund-of-funds or to allocate capital to outside GPs, keeping all investment activity inside its own fund vehicles.
How does Latterell Venture Partners source proprietary deal flow?
The firm sources heavily through relationships with academic medical centers — Stanford, UCSF, and the Mayo Clinic are in its natural orbit — and through practicing surgeons who encounter unmet clinical needs. This clinical-advisor network surfaces opportunities before they reach broad institutional syndication.
How is Latterell Venture Partners related to Morgenthaler Ventures?
Pat Latterell was a partner at Morgenthaler Ventures before founding Latterell Venture Partners. The firm carries forward the medical-device focus he built there, but Latterell Venture Partners is an entirely separate entity with its own funds and governance.
What is Latterell Venture Partners' track record with exits?
Public record shows notable exits including Ardian (acquired by Medtronic) and Acclarent (acquired by Johnson & Johnson). The firm's early-stage device focus means exits historically come through strategic acquisition by large med-tech companies rather than IPOs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: